-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Kazia Therapeutics, Maintains $18 Price Target

Benzinga·01/28/2026 13:37:46
Listen to the news
HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $18 price target.